Across TCGA pan-cancer cohorts, EZHIP mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EZHIP data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EZHIP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EZHIP expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC and GBM are the cancer types where EZHIP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.858	1.000	.031	8	view →
GBM	OS	Quartile	All	0.736	0.225	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: EZHIP tumor-vs-normal RNA expression · all EZHIP data types